Kai Xiong Cheong

Dr. Kai Xiong Cheong


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 September 2022 in American Journal of Ophthalmology
Verified
Journal Article
Closed access
KCKai Xiong Cheong
Kai Xiong Cheong
CCChui Ming Gemmy Cheung
Chui Ming Gemmy Cheung
KTKelvin Yi Chong Teo
Kelvin Yi Chong Teo

31 March 2022 in Survey of Ophthalmology
Verified
Journal Article
Closed access
KCKai Xiong Cheong
Kai Xiong Cheong
LXLingqian Xu
Lingqian Xu
KOKyoko Ohno-Matsui
Kyoko Ohno-Matsui
CSCharumathi Sabanayagam
Charumathi Sabanayagam
SSSeang Mei Saw
Seang Mei Saw
QHQuan V Hoang
Quan V Hoang

3 May 2023 in Diagnostics
Verified
Journal Article
Open access
PDF file
COCharles Ong
Charles Ong
MWMark Yu Zheng Wong
Mark Yu Zheng Wong
KCKai Xiong Cheong
Kai Xiong Cheong
JZJinzhi Zhao
Jinzhi Zhao
KTKelvin Yi Chong Teo
Kelvin Yi Chong Teo
TTTien-En Tan
Tien-En Tan
Traditionally, abnormalities of the retinal vasculature and perfusion in retinal vascular disorders, such as diabetic retinopathy and retinal vascular occlusions, have been visualized with dye-based fluorescein angiography (FA). Optical coherence tomography angiography (OCTA) is a newer, alternative modality for imaging the retinal vasculature, which has some advantages over FA, such as its dye-free, non-invasive nature, and depth resolution. The depth resolution of OCTA allows for characterization of the retinal microvasculature in distinct anatomic layers, and commercial OCTA platforms also provide automated quantitative vascular and perfusion metrics. Quantitative and qualitative OCTA analysis in various retinal vascular disorders has facilitated the detection of pre-clinical vascular changes, greater understanding of known clinical signs, and the development of imaging biomarkers to prognosticate and guide treatment. With further technological improvements, such as a greater field of view and better image quality processing algorithms, it is likely that OCTA will play an integral role in the study and management of retinal vascular disorders. Artificial intelligence methods—in particular, deep learning—show promise in refining the insights to be gained from the use of OCTA in retinal vascular disorders. This review aims to summarize the current literature on this imaging modality in relation to common retinal vascular disorders.

1 May 2021 in Ophthalmology Retina
Verified
Journal Article
Closed access
YSYoungseok Song
Youngseok Song
YTYih-Chung Tham
Yih-Chung Tham
CCCrystal Chong
Crystal Chong
RORicardo Ong
Ricardo Ong
BFBeau J. Fenner
Beau J. Fenner
CCChui Ming Gemmy Cheung
Chui Ming Gemmy Cheung

15 May 2024 in British Journal of Ophthalmology
Verified
Journal Article
Closed access
PDF file
KCKai Xiong Cheong
Kai Xiong Cheong
CZChenxi Zhang
Chenxi Zhang
TTTien-En Tan
Tien-En Tan
BFBeau J Fenner
Beau J Fenner
WWWendy Meihua Wong
Wendy Meihua Wong
YTYih Chung Tham
Yih Chung Tham
Background/aims: To compare the performance of generative versus retrieval-based chatbots in answering patient inquiries regarding age-related macular degeneration (AMD) and diabetic retinopathy (DR).Methods: We evaluated four chatbots: generative models (ChatGPT-4, ChatGPT-3.5 and Google Bard) and a retrieval-based model (OcularBERT) in a cross-sectional study. Their response accuracy to 45 questions (15 AMD, 15 DR and 15 others) was evaluated and compared. Three masked retinal specialists graded the responses using a three-point Likert scale: either 2 (good, error-free), 1 (borderline) or 0 (poor with significant inaccuracies). The scores were aggregated, ranging from 0 to 6. Based on majority consensus among the graders, the responses were also classified as ‘Good’, ‘Borderline’ or ‘Poor’ quality.Results: Overall, ChatGPT-4 and ChatGPT-3.5 outperformed the other chatbots, both achieving median scores (IQR) of 6 (1), compared with 4.5 (2) in Google Bard, and 2 (1) in OcularBERT (all p ≤8.4×10−3). Based on the consensus approach, 83.3% of ChatGPT-4’s responses and 86.7% of ChatGPT-3.5’s were rated as ‘Good’, surpassing Google Bard (50%) and OcularBERT (10%) (all p ≤1.4×10−2). ChatGPT-4 and ChatGPT-3.5 had no ‘Poor’ rated responses. Google Bard produced 6.7% Poor responses, and OcularBERT produced 20%. Across question types, ChatGPT-4 outperformed Google Bard only for AMD, and ChatGPT-3.5 outperformed Google Bard for DR and others.Conclusion: ChatGPT-4 and ChatGPT-3.5 demonstrated superior performance, followed by Google Bard and OcularBERT. Generative chatbots are potentially capable of answering domain-specific questions outside their original training. Further validation studies are still required prior to real-world implementation.

1 January 2021 in Survey of Ophthalmology
Verified
Journal Article
Closed access
KCKai Xiong Cheong
Kai Xiong Cheong
KTKelvin Yi Chong Teo
Kelvin Yi Chong Teo
CCChui Ming Gemmy Cheung
Chui Ming Gemmy Cheung